RT Journal Article
T1 Microvesicles from indoxyl sulfate-treated endothelial cells induce vascular calcification in vitro
A1 Alique, Matilde
A1 Bodega, Guillermo
A1 Corchete, Elena
A1 García-Menéndez, Estefanya
A1 Luque Pérez, Rafael
A1 De Sequera Ortiz, Patricia
A1 Rodríguez-Padrón, Daily
A1 Marqués, María
A1 Portolés, José
A1 Carracedo Añón, Julia María
A1 Ramírez, Rafael
AB Vascular calcification (VC), an unpredictable pathophysiological process and critical event in patients with cardiovascular diseases (CVDs), is the leading cause of morbi-mortality and disability in chronic kidney disease (CKD) patients worldwide. Currently, no diagnostic method is available for identifying patients at risk of VC development; the pathology is detected when the process is irreversible. Extracellular vesicles (EVs) from endothelial cells might promote VC. Therefore, their evaluation and characterization could be useful for designing new diagnostic tools. The aim of the present study is to investigate whether microvesicles (MVs) from endothelial cells damaged by uremic toxin and indoxyl sulfate (IS) could induce calcification in human vascular smooth muscle cells (VMSCs). Besides, we have also analyzed the molecular mechanisms by which these endothelial MVs can promote VC development. Endothelial damage has been evaluated according to the percentage of senescence in endothelial cells, differential microRNAs in endothelial cells, and the amount of MVs released per cell. To identify the role of MVs in VC, VSMCs were treated with MVs from IS-treated endothelial cells. Calcium, inflammatory gene expression, and procalcification mediator levels in VSMCs were determined. IS-treated endothelial cells underwent senescence and exhibited modulated microRNA expression and an increase in the release of MVs. VSMCs exposed to these MVs modulated the expression of pro-inflammatory genes and some mediators involved in calcification progression. MVs produced by IS-treated endothelial cells promoted calcification in VSMCs.
PB Computational and Structural Biotechnology Journal
SN ESSN: 2001-0370
YR 2020
FD 2020-04-09
LK https://hdl.handle.net/20.500.14352/6321
UL https://hdl.handle.net/20.500.14352/6321
LA eng
NO Instituto de Salud Carlos III (ISCIII)/Fondo Europeo de Desarrollo Regional (FEDER)
NO Universidad Complutense de Madrid /Banco de Santander
NO Universidad de Alcalá de Henares/Sociedad Española de Nefrología
DS Docta Complutense
RD 10 abr 2025